Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

And I think CRISPR and gene editing have been faster and ... I'll admit that when we were in maybe 2020, 2021, we were behind. I think Intellia was ahead with their in-vivo pipeline because ...

Learn how CASGEVY, the first NHS-approved CRISPR gene therapy, treats sickle cell disease through a revolutionary genetic ...

As layoffs continue to strike biopharma outfits big and small, life sciences technology and service provider Cytiva is ...

Colossal Biosciences has engineered mice with mammoth-like traits for living in cold climates. These mice have wavy, golden ...

Plectin drives hepatocellular carcinoma progression and metastasis through cytoskeletal reorganization and oncogenic signaling, making it a promising therapeutic target for overcoming therapy ...

Casgevy was the first drug to be licensed based on CRISPR, which earned its discoverers a Nobel Prize in 2020. The one-shot therapy is an ex vivo application of the technology, meaning that bone ...

an inherited form of blindness – was reported to be the first 'in vivo' CRISPR/Cas9 medicine to be administered to a patient when it started in 2020. EDIT-101 was delivered as an injection under ...

Here's why four Motley Fool contributors think chip giants Nvidia ( NVDA -0.26%) and Micron Technologies ( MU -1.05%), travel ...

Stock price predictions for 2025 are increasingly "meta." No, not the Facebook parent, but rather the idea that investments are increasingly self-referential rather than reliant on outside ...

Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple ...

Several hundred protesters rallied on Sproul before marching through campus as part of a nationwide Stand Up For Science protest Friday.